Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30817963 | 0.87 | DUT (0.36) | ADAMTS4MMP2MMP13MMP14P2RX7 | |
| SCHEMBL17979880 | 0.87 | DUT (0.36) | ADAMTS4MMP2MMP13MMP14P2RX7 | |
| SCHEMBL9009573 | 0.82 | TAAR1 (0.37) | — | |
| SCHEMBL31573468 | 0.79 | P2RX7 (0.34) | ADAMTS4MMP2MMP13MMP14P2RX7 | |
| SCHEMBL20220477 | 0.73 | SLC6A4 (0.36) | P2RX7 | |
| SCHEMBL9566318 | 0.73 | TAAR1 (0.39) | — | |
| SCHEMBL9566323 | 0.72 | SIGMAR1 (0.40) | — | |
| SCHEMBL17410221 | 0.71 | PYCR1 (0.36) | — | |
| SCHEMBL9009571 | 0.71 | — | — | |
| SCHEMBL6844318 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273883-B2 | Prostaglandin EP4 antagonist | ALLERGAN, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7217725-B2 | Prostaglandin D2 antagonist | ALLERGAN, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050065200-A1 | Prostaglandin EP4 antagonist | ALLERGAN, INC. (US) | 2005-03-24 | — | — | US | disclosed |
| US-20040162323-A1 | Prostaglandin D2 antagonist | ALLERGAN, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6716864-B2 | FOR THERAPY OF INFLAMMATORY REACTIONS RELATING TO RHEUMATOID ARTHRITIS AND PSORIASIS, REPRODUCTIVE DISORDERS, BRONCHOCONSTRICTIVE DISORDERS (ASTHMA), EXCESSIVE BONE BREAKDOWN (OSTEOPOROSIS), PEPTIC ULCERS, HEART DISEASE | ALLERGAN, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1317457-A2 | INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS | Allergan, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN INC. | 2003-06-05 | — | — | US | disclosed |
| US-6511999-B2 | Treating rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), osteoporosis, peptic ulcers, heart disease, and thrombosis | ALLERGAN, INC. | 2003-01-28 | — | — | US | disclosed |
| US-6509364-B2 | Antiinflammatory agents for reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, broncho-constrictive disorders, excessive bone breakdown, peptic ulcers, heart disease, platelet aggregation and thrombosis | ALLERGAN, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | ALLERGAN SALES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | ALLERGAN, INC. | 2002-09-12 | — | — | US | disclosed |
| US-6407250-B1 | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; OSTEOPOROSIS | ALLERGAN SALES, INC. | 2002-06-18 | — | — | US | disclosed |
| US-6369089-B1 | INFLAMMATORY REACTIONS RELATING TO RHEUMATOID ARTHRITIS AND PSORIASIS, REPRODUCTIVE DISORDERS, BRONCHOCONSTRICTIVE DISORDERS (ASTHMA), EXCESSIVE BONE BREAKDOWN (OSTEOPOROSIS), PEPTIC ULCERS, HEART DISEASE, PLATELET AGGREGATION AND | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002022620-A2 | INTERHETEROARYL 7-OXABICYCLIC [2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2$G(A) ANTAGONISTS | ALLERGAN, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165399-A1 | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists | PTGIR, PTGER1, TBXA2R | ADAMTS4 2174/4885MMP2 1972/4885MMP13 1388/4885 |
| US-20030105064-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | ADAMTS4 1778/4885MMP2 1667/4885MMP13 872/4885 |
| US-20020128233-A1 | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2alpha antagonists | PTGER1, PTGIR, PTGDR | ADAMTS4 1854/4885MMP2 1738/4885MMP13 768/4885 |
| US-20050065200-A1 | Prostaglandin EP4 antagonist | PTGER4, PTGER1, PTGER2 | ADAMTS4 2949/4885MMP2 2589/4885MMP13 1281/4885 |
| US-20040162323-A1 | Prostaglandin D2 antagonist | PTGDR2, PTGDR, PTGS1 | ADAMTS4 3554/4885MMP2 1935/4885MMP13 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.